antibiotics

IMPACT FACTOR 4.3

Indexed in: PubMed

CITESCORE 7.3

an Open Access Journal by MDPI

Antimicrobial Strategies to Limit Infection and Inflammation of Mucosal Surfaces

Guest Editors:

Prof. Dr. Mark Willcox
School of Optometry and Vision Science, University of New South Wales, Sydney, NSW 2052, Australia

Dr. Debarun Dutta
Optometry and Vision Science Research Group, Aston University, Birmingham, UK

Prof. Dr. Fiona Stapleton
School of Optometry and Vision Science, University of New South Wales, Sydney, NSW, Australia

Deadline for manuscript submissions:
closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

The mucosal surfaces of the body contain a diverse range of microbes which help to form a protective microbiome. This disruption can lead to overgrowth of the mucosal surface by potential pathogens and the development of inflammation and infection. The use of medical devices such as contact lenses, hearing aids, catheters and sanitary devices may also present new surfaces that can be colonized by potential pathogens.

This Issue seeks papers on the non-gastrointestinal-tract mucosal surfaces of humans—that is the eyes, ears, respiratory tract and urogenital systems. Papers on the normal microbiome of these mucosal surfaces and the consequences of antimicrobials and medical devices on the normal microbiome of these mucosal surfaces are welcome. We also encourage the submissions describing the development of new therapeutics to prevent or treat diseases of these systems, as well as clinical trials, observational studies, laboratory studies, etc. that provide new insights into these systems. Data on the effects of antimicrobial resistance on clinical outcomes are also encouraged.

Keywords: mucosal infection; medical device; microbiome; antimicrobial therapy

antibiotics

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 7.3

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
𝕏@antibioticsmdpi